Singapore O&G Ltd: Gaining market share August 13, 2018 1327

PSR Recommendation: BUY Status: Upgraded
Target Price: SGD0.42
  • 2Q18 Revenue/adjusted PATMI met 52.0%/61.1% of our full year estimations (Excluding the settlement fee receipt and legal fees from the dispute)
  • O&G segment performed well; 6M18 profitability +23.4% YoY despite. Number of deliveries increased despite a decline in industry deliveries. Dermatology a drag to group earnings.
  • Strong performance from cancer-related segment; 6M18 profitability +142.9% YoY.
  • Upgrade to BUY (previously ACCUMULATE) with an unchanged TP of S$0.42.

The Positives

+ O&G segment remains resilient. The obstetrics and gynaecology segments continue gaining market share (4.8% of 2Q18 Singapore total live births vs 4.1% a year ago). The O&G segment delivered 460 babies in 2Q18, rising 17.8% YoY. In contrast to Singapore’s birth rate of 0.66% YoY.

+ Cancer-related segment profits doubled. EBIT from O&G and cancer-related segments increased by 28.8% and 94.2% YoY, respectively, more than offset the challenging dermatology segment and ‘start-up’ losses incurred by the newly established paediatrics segment. 2Q18 EBIT margin for Cancer-related segment expanded from 19.3% to 28.2%, mainly due to Lim Siew Kuan who broke even in FY17 and her increase in patient load contributed positively to the earnings.

+ Higher interim dividend payout of 71.9% for 1H18 as compared to 70.2% in 1H17. The payout is based on earnings excluding the S$1.25mn legal settlement, tax effects and legal fees.

The Negatives

– Dermatology segment performance lacklustre due to a slowdown in medical tourism. 2Q18 EBIT declined -16.8% YoY and EBIT margin fell -6.4pps to 33.3%. The dermatology segment is reliant on medical tourism and marketing efforts are still targeted overseas through more channels to get the foreign patient load back.

The new Paediatrics segment incurred S$0.2mn ‘start-up’ losses to date. The 2 new paediatrician joined in July and November 2017. We expect both Paediatricians to breakeven by end-FY18.

Outlook

We are cautiously optimistic about FY18e. With a gradual recovery in birth rates in Singapore, and the Group’s ability to consistently gain market share in live births in Singapore, we expect the O&G segment to continue showing strong growth. We also expect the cancer-related segment to support Group’s FY18e profitability amidst persistent headwinds – (a) sluggish birth rate and (b) structural slowdown in medical tourism.

In addition, the Group launched the new HIFU treatment in July 2018 with 10 successful procedures performed so far. The Group is optimistic in the pick-up rate of this treatment in the unserved niche market for HIFU (High-Intensity Focused Ultrasound) treatment.

Lastly, the Group’s collaboration with SATA CommHealth is set up and it is only a matter of time before receiving referrals.

Upgrade to BUY (previously Accumulate) and unchanged TP of S$0.42, based on unchanged FY18e EPS of 1.82 cents and forward PER of 23.2x. SOG has a stable market position and its profitability from the O&G and Cancer-related segment has been improving as more doctors breakeven and gain more patient load. The Group is actively seeking suitable doctors to join its team to further grow its four business pillars. Management targets to add 2-3 new specialists by FY18e especially to the paediatrics segment. New doctors typically take 1 – 2.5 years to break even. The Group has a robust balance sheet with zero debt and a cash position of S$18.23mn (c.11% of its market cap).

Potential re-rating catalysts

  • Better-than-expected margin improvement, particularly its Cancer-related segment.
  • Faster-than-expected time to reach profitability for the Paediatric segment.
  • Expansion into other complementary medical services.

Other Updates

HIFU – an alternative treatment for uterine fibroid patients

  • HIFU (High-Intensity Focused Ultrasound) treatment is a non-surgical procedure to treat a uterine fibroid, using focused ultrasound energy. It can also be used to treat liver Expected benefits of HIFU treatment include low complication rate, non-invasive treatment thus faster recovery rate, and non-ionized radiation.
  • Lack of competitions in the Singapore and neighbouring markets.
    1. The machine manufactured by Chongqing Haifu Technology Co., Ltd. is supposedly one of the most effective HIFU machine available. Currently, only China, South Korea and Myanmar are providing HIFU treatment via this machine.
    2. Farrer Park Hospital is expected to bring in this machine in the coming With the introduction of this machine into Singapore, the Group believes that it could also attract foreign patients from the region.
    3. Only 4 gynaecologists in Singapore have undergone training to operate the machine, and 3 are from SOG, namely Lee Keen Whye, Dr. Beh Suan Tiong, and Dr. Hong Sze Ching.

Collaboration with SATA CommHealth

  • SOG will provide on-site medical services to SATA CommHealth with 50% profit sharing for an initial term of 12 months.
  • Hong Sze Ching will take lead to initiate the collaboration in the SATA Woodlands medical centre on 24 May-18.
  • While we do not expect a significant revenue generated from this collaboration, it allows the Group to expand its potential patient pool in the heartland areas.

S$1.25mn non-recurring item booked in 2Q18

Refer to the announcement dated 6 Mar-18, SOG has received the settlement amount of S$1.25mn for a settlement related to a dispute with its former Lead Independent Director, Mr. Christopher Chong Meng Tak.

Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE

Where the report contains research analyses or reports from a foreign research house, please note:

  1. recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
  2. to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!